Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for treating cancer as well as preparation method and application thereof

A composition and drug technology, applied in the field of medicine, can solve the problems of inability to effectively cure malignant tumors, hinder the curative effect, high toxicity, etc., and achieve the effects of inhibiting the growth of solid tumors, enhancing physical fitness, and low toxicity

Pending Publication Date: 2022-08-09
邓亚琴
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Chemotherapy drugs currently used clinically are highly toxic and have little effect, and cannot effectively cure malignant tumors
Targeted therapy and immunotherapy began to emerge in the late 1990s. Although they have a certain effect, the emergence of drug resistance genes is currently the main obstacle to further improving the efficacy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for treating cancer as well as preparation method and application thereof
  • Pharmaceutical composition for treating cancer as well as preparation method and application thereof
  • Pharmaceutical composition for treating cancer as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1 The pharmaceutical composition of the present invention

[0054] Formula: dimethyl sulfoxide 200mL, ethyl acetate 1mL;

[0055] Formula: 180mL of dimethyl sulfoxide, 1mL of ethyl acetate;

[0056] Formula: 160mL of dimethyl sulfoxide, 1mL of ethyl acetate;

[0057] Formula: dimethyl sulfoxide 140mL, ethyl acetate 1mL;

[0058] Formula: dimethyl sulfoxide 120mL, ethyl acetate 1mL;

[0059] Formula: dimethyl sulfoxide 100mL, ethyl acetate 1mL;

[0060] Formulation: dimethyl sulfoxide 80mL, ethyl acetate 1mL;

[0061] Formulation: dimethyl sulfoxide 60mL, ethyl acetate 1mL;

[0062] Formulation: dimethyl sulfoxide 40mL, ethyl acetate 1mL;

[0063] Formula: 20mL of dimethyl sulfoxide, 1mL of ethyl acetate;

[0064] Formulation: 1 mL of dimethyl sulfoxide, 1 mL of ethyl acetate.

Embodiment 2

[0065] Example 2 The pharmaceutical composition of the present invention

[0066] Formula: 200mL of dimethyl sulfoxide, 1mL of acetone;

[0067] Formula: dimethyl sulfoxide 180mL, acetone 1mL;

[0068] Formula: dimethyl sulfoxide 160mL, acetone 1mL;

[0069] Formula: dimethyl sulfoxide 140mL, acetone 1mL;

[0070] Formula: 120mL of dimethyl sulfoxide, 1mL of acetone;

[0071] Formula: 100mL of dimethyl sulfoxide, 1mL of acetone;

[0072] Formula: dimethyl sulfoxide 80mL, acetone 1mL;

[0073] Formula: 60mL of dimethyl sulfoxide, 1mL of acetone;

[0074] Formula: dimethyl sulfoxide 40mL, acetone 1mL;

[0075] Formula: 20mL of dimethyl sulfoxide, 1mL of acetone;

[0076] Formulation: 1mL of dimethyl sulfoxide, 1mL of acetone.

Embodiment 3

[0077] Example 3 The pharmaceutical composition of the present invention

[0078] Formula: 200mL of dimethyl sulfoxide, 1mL of ethanol;

[0079] Formula: dimethyl sulfoxide 180mL, ethanol 1mL;

[0080] Formula: 160mL of dimethyl sulfoxide, 1mL of ethanol;

[0081] Formula: 140mL of dimethyl sulfoxide, 1mL of ethanol;

[0082] Formula: 120mL of dimethyl sulfoxide, 1mL of ethanol;

[0083] Formula: 100mL of dimethyl sulfoxide, 1mL of ethanol;

[0084] Formula: 80mL of dimethyl sulfoxide, 1mL of ethanol;

[0085] Formula: 60mL of dimethyl sulfoxide, 1mL of ethanol;

[0086] Formula: 40mL of dimethyl sulfoxide, 1mL of ethanol;

[0087] Formula: 20mL of dimethyl sulfoxide, 1mL of ethanol;

[0088] Formulation: 1mL of dimethyl sulfoxide, 1mL of ethanol.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for treating cancers as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition contains or is composed of dimethyl sulfoxide and ester, ketone and alcohol compounds. The pharmaceutical composition provided by the invention has great value in prevention and treatment of cancers.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to a pharmaceutical composition for treating cancer and a preparation method and application thereof. Background technique [0002] The global medical community is almost at a loss for the treatment of cancer, that is, malignant tumors. The traditional treatment methods mainly include surgery, radiation therapy, and chemotherapy. Only a very small number of patients may be cured when they receive surgical resection at the early stage of the disease. The effect of radiotherapy is weak, and the existing chemotherapy drugs have limited effects, which can only maintain or prolong a short life. The currently used chemotherapeutic drugs have high toxicity and little effect, and cannot effectively cure malignant tumors. Targeted therapy and immunotherapy began to emerge in the late 1990s. Although there are certain curative effects, the emergence of drug resistance genes is currently the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/22A61K31/10A61K31/19A61K31/121A61K31/045A61P35/00A61P7/10A61P25/00A61P3/10A61P9/12A61P9/10A61P9/00A61P19/06A61P37/02A61P35/02A61P35/04
CPCA61K31/22A61K31/10A61K31/19A61K31/121A61K31/045A61P35/00A61P7/10A61P25/00A61P3/10A61P9/12A61P9/10A61P9/00A61P19/06A61P37/02A61P35/02A61P35/04A61K2300/00A61K31/21A61K31/12
Inventor 邓亚琴
Owner 邓亚琴
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com